- Home
- INCY vs CX Comparison
INCY vs CX Comparison
Compare INCY & CX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- CX
- Stock Information
- Founded
- INCY 1991
- CX 1906
- Country
- INCY United States
- CX Mexico
- Employees
- INCY N/A
- CX N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- CX Building Materials
- Sector
- INCY Health Care
- CX Industrials
- Exchange
- INCY Nasdaq
- CX Nasdaq
- Market Cap
- INCY 17.0B
- CX 12.2B
- IPO Year
- INCY 1993
- CX 1999
- Fundamental
- Price
- INCY $105.22
- CX $10.21
- Analyst Decision
- INCY Buy
- CX Buy
- Analyst Count
- INCY 19
- CX 7
- Target Price
- INCY $89.19
- CX $10.52
- AVG Volume (30 Days)
- INCY 2.8M
- CX 11.4M
- Earning Date
- INCY 10-28-2025
- CX 10-28-2025
- Dividend Yield
- INCY N/A
- CX 0.84%
- EPS Growth
- INCY 3878.02
- CX 231.88
- EPS
- INCY 5.90
- CX 0.09
- Revenue
- INCY $4,813,105,000.00
- CX $15,869,840,000.00
- Revenue This Year
- INCY $19.33
- CX $2.64
- Revenue Next Year
- INCY $10.47
- CX $4.82
- P/E Ratio
- INCY $17.95
- CX $10.82
- Revenue Growth
- INCY 18.09
- CX N/A
- 52 Week Low
- INCY $53.56
- CX $4.89
- 52 Week High
- INCY $106.47
- CX $10.45
- Technical
- Relative Strength Index (RSI)
- INCY 79.03
- CX 64.25
- Support Level
- INCY $91.16
- CX $9.90
- Resistance Level
- INCY $106.47
- CX $10.41
- Average True Range (ATR)
- INCY 4.10
- CX 0.28
- MACD
- INCY 1.59
- CX 0.04
- Stochastic Oscillator
- INCY 94.41
- CX 81.04
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.